Back

Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT

3 April 2025 (15:35 - 15:50)
Organised by: Logo
Congress Presentation Part of: From risk assessment to action: the role of icosapent ethyl in cardiovascular risk management Secondary Prevention Open Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Hussain Contractor

Manchester University Hospitals, Manchester (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Clinical Case Introduction
Professor V. Aboyans (Monaco, MC)
Slides Video
Presentation thumbnail
U-Prevent: a personalized approach to cardiovascular risk management
Doctor J. Dorresteijn (Utrecht, NL)
Slides
Presentation thumbnail
Key takeaways: addressing residual cardiovascular risk with proven therapies
Professor G. De Ferrari (Turin, IT)
Slides Video
Presentation thumbnail
Q&A
Slides

Access the full session

Session thumbnail
From risk assessment to action: the role of icosapent ethyl in cardiovascular risk management
Video

The Event

Event poster

ESC Preventive Cardiology 2025

3 April 2025 15:35 CET
You may be interested in
thumbnail
Congress Presentation
Managing a patient with residual risk: applying recent evidence with EPA to practice
thumbnail
Congress Presentation
Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-IT
thumbnail
Congress Session
Improving the management of patients with atherosclerotic cardiovascular disease: the evolving role of icosapent ethyl

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources